A Phase II Study of Tivozanib as Maintenance Therapy, Post-Chemotherapy, in Patients With Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Phase of Trial: Phase II
Latest Information Update: 08 Jun 2017
Price : $35 *
At a glance
- Drugs Tivozanib (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- 07 Aug 2015 Planned End Date changed from 1 Mar 2020 to 1 Jan 2016 as per ClinicalTrials.gov record.
- 07 Aug 2015 Status changed from recruiting to discontinued as per ClinicalTrials.gov record.
- 19 Feb 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.